Nurtec was supposed to be different. A newer class of drug. No vasoconstriction. No rebound risk. The "smart" migraine medication that blocks CGRP - the molecule researchers identified as central to migraine pain.
And for some people, it is different. It works beautifully. But for others, it does nothing. Or it helped for a while and then stopped. Or it takes the edge off but doesn't actually stop the migraine.
If Nurtec isn't working for you, it doesn't mean your migraines are untreatable. It means CGRP may not be the main driver of your attacks - and that's actually useful information.
Why this matters
CGRP has been called the "migraine molecule," but it's really just one molecule in a complex system. Blocking it helps when CGRP signaling is the dominant driver. When it's not - when histamine, blood flow, hormones, or autonomic instability are doing the heavy lifting - CGRP drugs like Nurtec won't address the actual problem.
What Nurtec Actually Does
Nurtec (rimegepant) is a gepant - a small-molecule CGRP receptor antagonist. CGRP (calcitonin gene-related peptide) is a neuropeptide released by trigeminal nerve fibers during a migraine. It causes blood vessel dilation, promotes neurogenic inflammation, and sensitizes pain pathways. Nurtec blocks the receptor that CGRP binds to, preventing these downstream effects.
Unlike triptans, Nurtec doesn't constrict blood vessels. This makes it safer for people with cardiovascular risk factors and means it doesn't carry the "wrong direction" risk that triptans can have in histamine-driven or perfusion-driven migraines.
But this specificity is also its limitation. Nurtec does one thing: block CGRP. If your migraine is being driven by something that CGRP blockade doesn't touch, it won't help.
Why Nurtec Doesn't Work for Some People
1. CGRP isn't your primary driver
CGRP is involved in most migraines to some degree, but it isn't always the dominant driver. In some migraine patterns, CGRP is more of a downstream effect than a root cause. When that's the case, blocking it is like treating the smoke instead of the fire.
Migraine patterns where CGRP may not be the primary driver include:
- Histamine-driven migraines - where vasodilation and neuroinflammation are mediated through histamine pathways, not primarily CGRP
- Perfusion-driven migraines - where the issue is inadequate blood flow to the brain, not excessive CGRP signaling
- Hormonal migraines - where estrogen withdrawal triggers cascades that may involve CGRP but are primarily driven by hormonal instability
- Central sensitization - where the pain processing has shifted to the brainstem and cortex, beyond what peripheral CGRP blockade can reach
2. Timing and absorption issues
Nurtec is an orally dissolving tablet (ODT), but it still takes time to reach therapeutic levels. Taking it too late in an attack - after central sensitization has set in (the "allodynia phase" where your scalp hurts, light is unbearable, and everything feels amplified) - can significantly reduce its effectiveness.
Nausea and gastroparesis (slowed stomach emptying), which are common during migraines, can also affect how much of the drug actually gets absorbed - even though the ODT dissolves in the mouth, a significant portion is still swallowed and absorbed through the gut.
3. The total load exceeds what one pathway can handle
Even when CGRP is involved, blocking it may not be enough if your total migraine load is high. Think of the threshold model: Nurtec removes one layer of input, but if poor sleep, stress, histamine, hormonal shifts, and dehydration are all contributing, removing one layer might not be enough to bring you below threshold.
This explains the "takes the edge off but doesn't stop it" experience. Nurtec is reducing CGRP-mediated input, but other pathways are still pushing you over.
4. Your migraine pattern changed
If Nurtec worked initially and then stopped, the drug likely didn't change - your migraines did. Common shifts include:
- Entering perimenopause (hormonal instability adds new load)
- Developing histamine sensitivity (new background amplifier)
- Worsened sleep or increased stress (nervous system load)
- New medication that affects other migraine pathways
- Seasonal or lifestyle change shifting the dominant driver
Nurtec vs Triptans: Why One Works When the Other Doesn't
Many people try triptans first and switch to Nurtec when they fail (or vice versa). Understanding why one works and the other doesn't can reveal what's driving your migraines:
Triptans work but Nurtec doesn't: Your migraines may be more driven by serotonin pathways and vascular tone than by CGRP. This pattern is more common in classic migraine with aura and in migraines that respond to vasoconstriction.
Nurtec works but triptans don't: Your migraines may be more CGRP-mediated, and the vasoconstriction from triptans may be unnecessary or even counterproductive. This is common in histamine-influenced patterns where triptans feel "tightening" and Nurtec provides cleaner relief.
Neither works: The primary driver may not be serotonin or CGRP. Consider vascular underfill, autonomic dysfunction, histamine overload, or hormonal instability as potential drivers that neither drug class addresses.
Both work but inconsistently: Your migraines may shift between mechanisms on different days. On CGRP-dominant days, Nurtec works. On serotonin-dominant days, triptans work. This inconsistency itself is a clue that multiple pathways are involved, and the variable is which one dominates on a given day.
Preventive vs Acute: Why One Mode May Work and the Other Doesn't
Nurtec is unique in being approved for both acute treatment and prevention (75mg every other day). But some people find it works acutely and not preventively, or the reverse. This isn't random - it reflects different aspects of your migraine pattern.
Works acutely, not preventively
CGRP is involved in your acute attacks but isn't the reason you're having them so frequently. The chronic pattern may be driven by hormonal cycles, sleep disruption, or histamine load - factors that continuous CGRP blockade doesn't address.
Works preventively, not acutely
Continuous CGRP suppression may be keeping your baseline load low enough to prevent some attacks, but once an attack begins and other pathways activate, CGRP blockade alone isn't enough to abort it.
This Pattern May Fit You If
- • Nurtec reduces pain but doesn't fully stop your migraines
- • It worked for a while and then became less effective
- • Triptans also don't work well (or at all)
- • Your migraines come with flushing, congestion, or food reactions (suggesting histamine involvement)
- • Migraines are clearly tied to hormonal shifts, posture changes, or hydration status
- • You've tried multiple medications and none fully work
- • You respond differently to Nurtec on different days
What to Discuss With Your Clinician
If Nurtec isn't working as expected, these questions may help guide the conversation:
- • Whether to try Nurtec acutely vs preventively (or both) if you've only tried one mode
- • Whether histamine, hormonal, or vascular pathways should be investigated as alternative drivers
- • Whether combining Nurtec with a triptan (on different occasions) might cover different migraine subtypes
- • Whether a CGRP monoclonal antibody (Aimovig, Ajovy, Emgality) might provide more sustained CGRP suppression than the intermittent approach
- • Whether addressing underlying load factors (sleep, sodium, stress, hormones) could improve Nurtec's effectiveness by reducing the total load it needs to counteract
The Part Most People Miss
The "migraine molecule" narrative makes CGRP sound like the whole story. It isn't.
CGRP is one important pathway in a system with many. When Nurtec doesn't work, it doesn't mean you're out of options - it means CGRP isn't where your system is under the most pressure. That's not a dead end. It's a signal to look at the other pathways: histamine, blood flow, hormones, autonomic regulation, and the load factors that determine whether any given day crosses your threshold.
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet. 2019;394(10200):737-745.
- Lipton RB et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine prevention. New England Journal of Medicine. 2021;384(11):1049-1058.
- Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(S2):47-55.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.